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Introduction
Castleman’s disease (CD) or angiolymphoid vascular
hyperplasia is a rare and not well recognized disease of
unknown etiology characterized by a massive growth of
lymphoid tissue that was first described in 1954, and
subsequently better defined by Castleman in 1956.
It usually appears in young adults whilst it rarely occurs
in childhood. There are only about 100 pediatric cases
published. CD is believed to be autoinflammatory in
pathology and result in increased interleukin-6 secretion.
Previous studies in adult patients suggested beneficial role
of the anti-interleukin-6 receptor antibody tocilizumab in
treatment of CD. We report 3 cases of multicentric
Castleman’s disease in children, treated in our center in
recent years.
Objectives
To assess efficacy of tocilizumab therapy in children
with Castleman’s disease.
Methods
3 patients ages 4, 14 and 16 were diagnosed with multi-
centric Castleman’s disease on the basis of clinical and his-
tologic findings. 2 children (the boy of 4 years and the girl
of 14 years) had hyaline-vascular type of CD, the boy of
16 years had plasma cell type of CD. The duration
of illness before the correct diagnosis and beginning of
treatment in the younger boy was 6 months, in the girl
and the older boy - 6 years. All patients had enlarged
lymph nodes of several groups and systemic involvement
with fevers, weight loss, ascites, and progressive hematolo-
gical changes (thrombocytopenia, anemia, high CRP).
HHV-7 and 8 staining of the tissues were negative. In all
cases treatment with tocilizumab as monotherapy was
started at a dose of 8 mg/kg every 2 weeks.
Results
2 infusions in 2 children and 1 in one was performed.
During the treatment period lymph nodes’ sizes slightly
decreased two patients and no lymph nodes size change
was noted in the third patient. All patients continued to
have progression of systemic symptoms. Therefore,
Tocilizumab treatment was discontinued and substituted
with more aggressive protocols consisting of cyclopho-
sphamide, vincristine, prednisone and rituximab with
fast effect: two children now are disease-free, the third
one has marked improvement.
Conclusion
Tocilizumab has been reported to be effective for treat-
ment of adults with CD, yet it proved insufficient activ-
ity in our three pediatric cases. In our experience CD in
children has more aggressive course, therefore requiring
chemotherapy aimed at lymphocytes’ reduction.
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